About Hanmi

한미약품은 창조와 도전을 기치로 신약개발에 매진하는 R&D중심 제약기업입니다.



  • Jun. LAPSGlucagon Analog receives FDA RPD designation
  • LAPSGLP-2 Analog receives FDA RPD designation
  • Spectrum presents clinical trial results of Rolontis at AACR
  • Gugu' released In Japna as a BPH treatment
  • Announced 6 new clinical trial results at ADA
  • Released low-dose Amodipine(2.5mg)
  • Spectrum presents Phase 2 clinical trial results of Oraxol
  • May. Hanmihealthcare donated 156,000 'Wanjun' soymilk
  • Applies Rolontis BLA to the KFDA
  • Apr. Launched 'LIVE Symposium 2020'
  • Announced 2020 1Q earnings 288.2 billion won in sales, 19% R&D investment against sales
  • Hanmi Pharmaceutical set up an audit committee
  • Mar. LAPSTriple Agonist receives FDA RPD desination for PSC and PBC
  • Feb. Announced 2019 earnings 1.16 trillion won in sales, 18.8% R&D investment against sales
  • JVM Packaging System, Launched in Canadian Walmart
  • Announced 2019 earnings 110.1 billion won, increased 6.3 percent on-year
  • Hanmi announces the largest number of blockbuster products in 2019.
  • Signed a partnership with GC to develop Rare Disease new drugs
  • Jan. Announced achieving 'Top 1' market share of hypertension medication in Korea
  • A Joint agreement with STANDIME on the Development for new drugs based on AI
  • Hanmi unveiled new R&D strategy at 38th JP Morgan Healthcare Conference
  • Certified International Standard for business countinuity Management System (ISO22301)